Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NFXOeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfBNQKBmzFyMECg{txu M2PXWlI1KGkEoB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M37mflI3ODh6N{Gx
POLK WT NUfDRVVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnN[lVKSzVyPUGxMlfjiIoEsfMAjVEvP8LizszN NYDKN2g2OjZyM{G0NFA>
POLK KO NGnme49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e3O2lEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN M1fnT|I3ODNzNECw
POLK CD MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK5TWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= Ml7kNlYxOzF2MEC=
RLE/Abca3 MX;GeY5kfGmxbjDBd5NigQ>? M2OyfFAvPMLizszN MnPsNVQ1yqCq MYjpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi Mn7LNlU4PjB3M{i=
PMCs NHXqU4NHfW6ldHnvckBCe3OjeR?= NHTCOWUxNjIkgKOyxsDPxGdxbXy= NF;GdI0zPMLiaB?= M2j4Z4NifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= M{TtbVI2PTl3NkSy
PMCs M1jlW2Z2dmO2aX;uJGF{e2G7 NILONlgxNjMEoN88[{9udA>? MofWNlTjiJN5MtMgbC=> MYTpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> MWOyOVU6PTZ2Mh?=
PMCs NX21bY92TnWwY4Tpc44hSXO|YYm= MnH5NE4zyqEQvHevcYw> MXu3NkBp NVHSS5hPcW6mdXPld{Bl\WO{ZXHz[ZMhcW5iY4n0c4tmemG2aX6tPEBidmRiRT3jZYRp\XKrbjDwdo91\Wmw M{TjWlI2PTl3NkSy
PMCs Mn;FSpVv[3Srb36gRZN{[Xl? NH3KTXgxNjMEoN88[{9udA>? MoDENVIwOjRxNEigbC=> MmfFbY5kemWjc3XzJINmdGxibXnndoF1cW:w NWK5TFZyOjV3OUW2OFI>
IMR-32 M4LnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3MlXjkJJzMkCgxtVoN22u NEf4epEyOuLKkkS4JIg> NXv6VVBNUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= NIPTV|EzPTV|NkO0OS=>
HT1080 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCNUDPxE1? M1XuNlI1KGkEoB?= MXXs[YFleyC2bzDhJGczN01iZHXsZZk> MX2yOVUyQDl4MR?=
HT1080 M1TVeWZ2dmO2aX;uJGF{e2G7 NFnPR2EyKM7:TR?= MUOyOEBpyqB? Mm\ZbY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= M3nSOVI2PTF6OU[x
HDFn MmHlR5l1d3SxeHnjbZR6KEG|c3H5 NV3SSWRVPzJiaB?= MY\JR|UxRTlwM{GlxsA> NWTaS3ZzOjV{N{[3PVI>
THP-1 NXvWcGJLS3m2b4TvfIlkcXS7IFHzd4F6 MnLkO|IhcA>? MnfrTWM2OD12Lke3KS=> NU\3NHA2OjV{N{[3PVI>
HT-29 MVjDfZRwfG:6aXPpeJkhSXO|YYm= NFjFT5U4OiCq NHiwRo1KSzVyPUGxMlQ6LQ>? Mn7KNlUzPzZ5OUK=
HCT116  NY\qWJB6S3m2b4TvfIlkcXS7IFHzd4F6 NHvzRm84OiCq M3nwRWlEPTB;MUGuN|Qm NFfLZ4QzPTJ5Nke5Ni=>
A431 NFPuRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG1NE0zODBiSWW= MUi0PQKBkWh? MXfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXOyOVExOTJ7OR?=
T24 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfUN5A2OC1{MECgTXU> NYW4bnVJPDkkgJno MoPnbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NGTnflkzPTFyMUK5PS=>
AY-27  M16zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zk[|UxNTJyMDDJWS=> NX\McHVyPDkkgJno NIrtdnNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmTQNlUyODF{OUm=
A549 MYTGeY5kfGmxbjDBd5NigQ>? MmfYNUDDvWdxbV|CpC=> NXfMOHN7OC12ODDo NW\jWoVjcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? NUXIWHBJOjR7NkO2N|U>
MLE12 NVX0bWg1TnWwY4Tpc44hSXO|YYm= MYOxJOK2\y:vTNMg M4f0UVAuPDhiaB?= M4ryNYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C NX;FUXFVOjR7NkO2N|U>
Jurkat MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJNlDjiIoQvH2= MViyOQKBkWkEoB?= NHzGVI1ienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? M2fQXlI1QTF4OEmz
HeLa  M2rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFyLkNCpO69VQ>? M3rPSFI1PzN{M{m3
C18-4 NV7hfm5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETuc|IxNTFyMDFOwG0> MkS0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmPvNlQ2PzF7OEK=
BMG-1  NGD0WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj1[Xo1OC96MNMg{txoN21? MnLTN:KhcA>? MWXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVOyN|kxPjd{Nh?=
A459 MnTuRZBweHSxc3nzJGF{e2G7 NETQXXYyOCCvVR?= MXK0PEBp MUPpcoR2[2W|IHHwc5B1d3Orcx?= M1nxb|I{QTB{N{[2
MOCK NILjVYZCeG:ydH;zbZMhSXO|YYm= MUmxNEBuXQ>? MnnEOFghcA>? NVfaNnR2cW6mdXPld{BieG:ydH;zbZM> M1;oXVI{QTB{N{[2
MMP1 NGXIT2tCeG:ydH;zbZMhSXO|YYm= MWKxNEBuXQ>? MUi0PEBp NYCwe2VTcW6mdXPld{BieG:ydH;zbZM> M1nSWFI{QTB{N{[2
A549 NUXWdXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITBXZgzODBizszN MUOyOEBpyqB? MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NEXJTYIzOzhyNUe5Ny=>
HCT-116 M17SNGFxd3C2b4Ppd{BCe3OjeR?= MmXON{84NjVxMUWg{txoN22u M2L6VFQ5KGh? NF3IVZlz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v NUK4VZc3OjN5MEi2Olg>
HeLa MnT6RZBweHSxc3nzJGF{e2G7 M3G5UFMwPy53L{G1JO69\y:vbB?= Mn7NOFghcA>? NX3LXZVjemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? MmK3NlM4ODh4Nki=
HCT116 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfnOGExNTFyMDFOwIcwdWx? NIDaN2o1QCCq MkPibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2j1cVI{PTF6MkCx
NCM460 NGK0fHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\aWmJ5OC1zMECg{txoN22u NUniOVNvPDhiaB?= NUfoboRVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MYOyN|UyQDJyMR?=
NT2  MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfMUJE{OjRiaNMg MWHMSFUxRTRyMPMAjeK2\y:vbB?= MlPENlM{QDZ2MkC=
NT2  M3[4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITCZYI1QCCq MnTyUGQ2OD1zMECgxtVoN22u MWCyN|M5PjR{MB?=
NT2  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknjO|IhcA>? Mmn6UGQ2OD1{MPMAjeK2\y:vbB?= NFnhRlIzOzN6NkSyNC=>
NT2  NFrCNlJCeG:ydH;zbZMhSXO|YYm= M4Die|QxOOLCidM1[{9udA>? NEXOfVkzPCCqwrC= NVnvOWZicW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi MVSyN|M5PjR{MB?=
NTera-2 MXPGeY5kfGmxbjDBd5NigQ>? NIH4WY0yOjBizsznM41t MmizO|IhcA>? M2H5OpNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz Mnn4NlI5OjV|NUW=
NCCIT NYPZbox6TnWwY4Tpc44hSXO|YYm= M17LXVEzOCEQvHevcYw> NXnCOnk4PzJiaB?= M{nEO5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz MUCyNlgzPTN3NR?=
NTera-2 NX;mTZZMTnWwY4Tpc44hSXO|YYm= NE\zeo4yOjBizsznM41t MXS3NkBp NF7kUXh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> M4jFZlIzQDJ3M{W1
NCCIT NES4fFlHfW6ldHnvckBCe3OjeR?= NFTMZ4oyOjBizsznM41t M1vkNVczKGh? NH;xbY9{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MVWyNlgzPTN3NR?=
NCCIT Ml7qSpVv[3Srb36gRZN{[Xl? NIHBXocyOjBizsznM41t MX23NkBp NHXRUol{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDHV2ghdGW4ZXzz NUnrfFZjOjJ6MkWzOVU>
NTera-2 NWf3PXJlTnWwY4Tpc44hSXO|YYm= NUXxeZJtOTJyIN88[{9udA>? M33xTlczKGh? M1rzZpNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ NYPacpJkOjJ6MkWzOVU>
NCCIT NUnIc|VGTnWwY4Tpc44hSXO|YYm= MW[xNlAh|rypL33s NVPZSJFbPzJiaB?= NEjrfYh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? MYOyNlgzPTN3NR?=
NTera-2 MkDTSpVv[3Srb36gRZN{[Xl? NH7JUY0yOjBizsznM41t M1LFTFczKGh? M3LISJNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NGnqbJUzOjh{NUO1OS=>
NCCIT NVvrcmwxTnWwY4Tpc44hSXO|YYm= NYL4U|d[OTJyIN88[{9udA>? NFv4emg4OiCq MkTWd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MWqyNlgzPTN3NR?=
MDA-MB-468 M3:0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjpOHR[OOLCk{KwNOKh|rypL33M MnPLNlQhcA>? NGPMSIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NFThOmEzOjhzOUG5Oi=>
231-H2N NHj1W5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUew5qCUOjBywrFOwIcwdUx? MYSyOEBp NUnnbIJucW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NHfG[lgzOjhzOUG5Oi=>
A549  NYPwXVZtTnWwY4Tpc44hSXO|YYm= NYK1N3FOOjByL{SwNEDPxE1? NF7H[5Zz\XO3bITzJIlvKGFiZH;z[U1z\XOyb37zbZZmKGmwY4LlZZNmKGmwIGLPVy=> NIXoVlIzOjd5M{[5Oy=>
A549  MUTGeY5kfGmxbjDBd5NigQ>? M3z5U|AuPDByIN88US=> NF7i[5MzNTR6IHi= NHvzeWRk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl NEPO[VIzOjd5M{[5Oy=>
A549  NFyzOnhHfW6ldHnvckBCe3OjeR?= NFHQOFYyODBizszNxsA> MYiw5qCUPDhiaB?= NHrldpZk[XW|ZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NWjmfIhFOjJ5N{O2PVc>
A549  NULGVIVLTnWwY4Tpc44hSXO|YYm= NFT2PGoyODBizszNxsA> NH\iWIUx6oDVNEigbC=> Mmf4Z4F2e2W|IGDLSFEh[2ynYY\h[4U> MUmyNlc4OzZ7Nx?=
A549  Ml\CSpVv[3Srb36gRZN{[Xl? M3;hSlExOCEQvF5CpC=> Mn7nNQKBmzR6IHi= MYrjZZV{\XNibXn0c4Npd26mcnnhcEBtd2OjbHn6ZZRqd25ib3[gRoF5 NVy3[Y1vOjJ5N{O2PVc>
A549  MWrGeY5kfGmxbjDBd5NigQ>? MkfyNVAxKM7:TdMg NYLDW2hLOOLCk{S4JIg> MV;k[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz MlGxNlI4PzN4OUe=
MCF-7/Her-18  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17od|AvPDJvMUewNEDPxGdxbVy= MUmyOEBp M3vPXolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3TLN|IzPjJzNEC0
MCF-7 NHrOeVFRTFRxUFPJJHRz\WG2bXXueC=> MUWwMlI2KM7:Zz;tcE4> MUGxMVQhcA>? MUTzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 NHixcYozOjV7MUK4OC=>
MDA-MB-231 M{KwNnBFXC:SQ1mgWJJm[XSvZX70 NHXpNpAxNjJ3IN88[{9udC5? MlK4NU01KGh? NVLQd2tTe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MYWyNlU6OTJ6NB?=
MDA-MB-235  MWjQSHQwWEOLIGTy[YF1dWWwdB?= M4jDNFAvOjVizsznM41tNg>? MoT3NU01KGh? NF;odYx{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NIPXSnczOjV7MUK4OC=>
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonoNE0zKM7:Zz;tcE4> MlPoNlQwPDhiaB?= NXTTS2lyTUN3ME2xMlIh|rypL33M M1zhN|IzPTlzMki0
NCCIT  NGj2clNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj0U4QzOOLCk{G0NOKh|rypL33s Ml:2O|IhcA>? M3vxc2xFPTB;MUKwxsDPxGdxbX|CpC=> M{[wNlIzPTZ{MU[w
NCCIT  MXzGeY5kfGmxbjDBd5NigQ>? M37LW|czKGh? NV3ieJhHe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> MWeyNlU3OjF4MB?=
NCCIT  MV7GeY5kfGmxbjDBd5NigQ>? MV[3NkBp NXi0SJh2e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFkfGm4aYT5xsA> Mkj5NlI2PjJzNkC=
NCCIT  M3jP[GZ2dmO2aX;uJGF{e2G7 MkTTO|IhcA>? MkC1d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S17IHHjeIl3cXS7wrC= MkSxNlI2PjJzNkC=
NCCIT  MU\GeY5kfGmxbjDBd5NigQ>? MkTBO|IhcA>? Mn3od4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MkPVNlI2PjJzNkC=
NCCIT  NGDtfHlHfW6ldHnvckBCe3OjeR?= MVi3NkBp NGTVWYZ{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= NH65PFIzOjV4MkG2NC=>
NCCIT  MkXJSpVv[3Srb36gRZN{[Xl? M2fXVlczKGh? NVvEcm56e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEO7dD3jJIxmfmWu NHS1[nIzOjV4MkG2NC=>
HeLa M3XkdGZ2dmO2aX;uJGF{e2G7 M3\pW|MxNzdyIN88[{9udA>? NYDqbpYxOjUEoHi= NHX5bJdqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? M{LDZ|IzPDh5OUO3
MCF-7  MWHGeY5kfGmxbjDBd5NigQ>? NFTZbI8{OC95MDFOwIcwdWx? NXPNUpdQOjUEoHi= MX3pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> M3WxblIzPDh5OUO3
HeLa NX62ZVg1S3m2b4TvfIlkcXS7IFHzd4F6 MYizNE84OCEQvHevcYw> NUPOfoM6OjUEoHi= M3fuVYlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= M1vjSlIzPDh5OUO3
MCF-7  MofER5l1d3SxeHnjbZR6KEG|c3H5 NEPiOJY{OC95MDFOwIcwdWx? NGe2[m0zPMLiaB?= MnvJbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv Mo[3NlI1QDd7M{e=
NT2 M2TiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PyblExOC14MEFCpO69\y:vbB?= MVeyOEBp M4PEWGlEPTB;NECwJOK2\y:vbB?= NUnUfG1XOjJ2Nkm5OVI>
NT2 M2PHWGZ2dmO2aX;uJGF{e2G7 MVK0NFDDqM7:Zz;tcC=> NV7MdHdTOjRiaB?= MXnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> M2PHR|IzPDZ7OUWy
NT2 MlHESpVv[3Srb36gRZN{[Xl? Mnv6OFAxyqEQvHevcYw> NHz6UHgzPCCq M3LwRpNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= NXzrb5JJOjJ2Nkm5OVI>
NT2 M{XwWGZ2dmO2aX;uJGF{e2G7 MkjmOFAxyqEQvHevcYw> NFfJRoEzPCCq Ml7ld4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= MmfkNlI1Pjl7NUK=
CHO NF;PeVRHfW6ldHnvckBCe3OjeR?= NYm3cm9xOi53wrFOwIcwdWx? NG\afHMyQCCqL{[g[C=> NGHlOnFqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= NUeyOpRbOjJ{M{CxPVU>
Jurkat NGX6c4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrMOoQxNTFyMNMg{txoN22u MmLtNlQhcA>? MYPhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> MkLwNlIzOjN|M{K=
Jurkat MXjGeY5kfGmxbjDBd5NigQ>? NFnHS3o{OMLizsznM41t M3;FWFI1KGh? NXf1[mtGcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> MYqyNlIzOzN|Mh?=
Jurkat NVPNTHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r4VVAuOTBywrFOwIcwdWx? MYqyOEBp NX:wbolFcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigZY4hUUN3MDD2ZYx2\SCxZjCxNFDPxGdxbVy= MUeyNlIzOzN|Mh?=
Jurkat M1LSWGZ2dmO2aX;uJGF{e2G7 MmnQN|DDqM7:Zz;tcC=> MnXkNlQhcA>? MWrpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? MYqyNlIzOzN|Mh?=
U2OS EGFPnls NUTk[lJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nKV|AuOsLizsznM41t M1zMU|I1KGh? MXfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MlnUNlE5OTFyMEe=
U2OS KuEnls NX7tZ5ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npcVAuOsLizsznM41t Mk\GNlQhcA>? Mkj3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NU[0flc{OjF6MUGwNFc>
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzT|AuPDByIN88US=> MVW3NkBp MUXMR|UxRTF3MT64xsDPxE1? MonhNlE4ODN{OUG=
MCF-7/Adr  MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnWZZNDOC12MECg{txO NGPrcoI4OiCq NWe4eHRCVEN3ME21PE42yqEQvF5CpC=> MlPkNlE4ODN{OUG=
WI-38 NUfWVnhtTnWwY4Tpc44hSXO|YYm= M{DTPVAwPDBxOEFihKnPxGdxbX|CpC=> MXmzJIg> NF\qRnpqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NIDwU3YzOTV7OU[xNi=>
hBMSC M3XVVmZ2dmO2aX;uJGF{e2G7 NYrTT2o6OC92MD:4NQKBkc7:Zz;tcOKh NEnxPI8{KGh? NHvUZYFqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NWTsPIdVOjF3OUm2NVI>
NCI-H23 NEmwTVlHfW6ldHnvckBCe3OjeR?= MkjZNE81OC96MPMAje69\y:vbNMg NFvRWYk{KGh? Mk\mbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NX3NVWJEOjF3OUm2NVI>
A-549 NXT1To1ZTnWwY4Tpc44hSXO|YYm= NVXZc3NTOC92MD:4NQKBkc7:Zz;tcOKh MXyzJIg> MmLvbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NVu1XlZxOjF3OUm2NVI>
PBL  NXHFTnlJTnWwY4Tpc44hSXO|YYm= M2joSlAwPDBxOEFihKnPxGdxbX|CpC=> NYnLVo1xOyCq NGL5W2RqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MojTNlE2QTl4MUK=
pol β −/− NWfmfnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3nNE4zPS1{MEFCpO69\y:vbB?= MXmyOOKhcA>? NX;G[Xhj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MYGyNVI2OTl2NB?=
pol β +/+ NWXtbZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom1NE4zPS1{MEFCpO69\y:vbB?= M3rTXFI1yqCq NGLDfoNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? MnXlNlEzPTF7NES=
pol β −/− MkDKSpVv[3Srb36gRZN{[Xl? M1P2VFAuOi53IN88[{9udA>? MV6yJIg> NIPhT3hk[XW|ZYOgSG5CKGSjbXHn[S=> MYKyNVI2OTl2NB?=
pol β +/+ M4LpOmZ2dmO2aX;uJGF{e2G7 MYSwMVIvPSEQvHevcYw> NX:zfGZsOiCq M2fheYNifXOnczDEUmEh\GGvYXfl NV3pOo95OjF{NUG5OFQ>
pol β −/− NVLEWpI2TnWwY4Tpc44hSXO|YYm= NYPVPXgyOC13IN88[{9udA>? NHPXbY01QCCq MkP4Z4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M3j1e|IyOjVzOUS0
pol β +/+ M4ezVWZ2dmO2aX;uJGF{e2G7 M4fYVVAuPSEQvHevcYw> MnnnOFghcA>? NHHVV|Nk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MmL6NlEzPTF7NES=
TK6  NWXLZm9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLOW41uOjVvMUWwJO69\y:vbB?= NYfhcIloQTZiaB?= MUDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFjpdXczOTB6MUS4Oy=>
TK6  sLUC+Apn1 NHX2W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvJfGYzPS1zNUCg{txoN22u NHy5Ong6PiCq M1PQVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MVSyNVA5OTR6Nx?=
TK6 sAPE1+Apn1 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXkNlUuOTVyIN88[{9udA>? M2L2bFk3KGh? NX;C[2t2e2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGXq[IwzOTB6MUS4Oy=>
HCT116 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2yOU0yPTBizsznM41t MkLmPVYhcA>? NX;Vb2VNcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUCyNVA5OTR6Nx?=
HCT116 sLUC+Apn1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH62[nozPS1zNUCg{txoN22u NUnWWoVJQTZiaB?= Mnn1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmD5NlExQDF2OEe=
HCT116 sAPE1+Apn1 NXvZdJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWzNlUuOTVyIN88[{9udA>? MYS5OkBp MUjzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? M3\xWVIyODhzNEi3

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children''s Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01132807 Completed Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT01026220 Completed Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Children''s Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID